Merck inks deal with Xian Janssen for type 2 di­a­betes drug

BioSpectrum (Asia) - - Company News -

Global drug gi­ant, Merck has signed an agree­ment with China’s Xian Janssen Phar­ma­ceu­ti­cals in Bei­jing re­cently, to launch type 2 di­a­betes drug INVOKANA (canagliflozin) in China.

Through this agree­ment, the two com­pa­nies will work closely to­gether on fu­ture de­vel­op­ment, dis­tri­bu­tion, pro­mo­tion, ac­cess, mar­ket­ing and sales of INVOKANA in the coun­try and Merck will hold the ex­clu­sive rights for INVOKANA’s pro­mo­tion in China.

INVOKANA is a mem­ber of a novel class of drugs known as sodium-glu­cose co-trans­porter 2 (SGLT-2) in­hibitor and was ap­proved in China in Septem­ber 2017. INVOKANA is ap­proved for treat­ment of type 2 di­a­betes in com­bi­na­tion with met­formin or with met­formin plus sul­fony­lurea in adults who have not achieved ad­e­quate gly­caemic con­trol on these oral ther­a­pies.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.